This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Neurology  • Meningitis  • Public Health, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

New Outbreaks, New Strategies

Jay D. Wenger, MD

JAMA. 1999;281:1541-1543.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Meningococcal disease is among the most feared infections of children and young adults because of the rapidity of onset, high mortality rate, devastating sequelae, and tendency to spread and cause outbreaks. Two articles in this issue of THE JOURNAL^1-2 highlight the challenge of serogroup B meningococci—the most common cause of meningococcal disease in many countries.

Meningococci are commonly classified based on serologic reactivity of their polysaccharide capsules. At least 13 serogroups have been identified, but serogroups A, B, and C strains are the most common causes of human disease. Serogroup A organisms can cause massive outbreaks, and in some areas, such as the African meningitis belt, countrywide epidemics with attack rates approaching 1 to 2 cases per 100 persons per year strike repeatedly. In other areas, including the Americas and Europe, serogroups B and C cause most meningococcal disease. In North America and Western Europe, multiple . . . [Full Text of this Article]

Author Affiliation: Expanded Programme on Immunization, Vaccines and Other Biologicals, Health Technology and Pharmaceuticals, World Health Organization, Geneva, Switzerland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Epidemic Serogroup B Meningococcal Disease in Oregon: The Evolving Epidemiology of the ET-5 Strain
Marion Diermayer, Katrina Hedberg, Frederick Hoesly, Marc Fischer, Bradley Perkins, Michael Reeves, and David Fleming
JAMA. 1999;281(16):1493-1497.
ABSTRACT | FULL TEXT  

Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines: A Randomized Controlled Trial in Chile
Jordan W. Tappero, Rosanna Lagos, Aurora Maldonado Ballesteros, Brian Plikaytis, Derrick Williams, Janet Dykes, Linda L. Gheesling, George M. Carlone, E. Arne Høiby, Johan Holst, Hanne Nøkleby, Einar Rosenqvist, Gustavo Sierra, Concepción Campa, Franklin Sotolongo, Jeanette Vega, Julio Garcia, Patricio Herrera, Jan T. Poolman, and Bradley A. Perkins
JAMA. 1999;281(16):1520-1527.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Phase II meningococcal B vesicle vaccine trial in New Zealand infants
Jackson et al.
Arch. Dis. Child. 2009;94:745-751.
ABSTRACT | FULL TEXT  

Comparison and Correlation of Neisseria meningitidis Serogroup B Immunologic Assay Results and Human Antibody Responses following Three Doses of the Norwegian Meningococcal Outer Membrane Vesicle Vaccine MenBvac.
Findlow et al.
Infect. Immun. 2006;74:4557-4565.
ABSTRACT | FULL TEXT  

Phenotypic characterization of Neisseria meningitidis strains isolated from invasive disease in Brazil from 1990 to 2001
Lemos et al.
J Med Microbiol 2006;55:751-757.
ABSTRACT | FULL TEXT  

Vaccine Potential of the Neisseria meningitidis 2086 Lipoprotein
Fletcher et al.
Infect. Immun. 2004;72:2088-2100.
ABSTRACT | FULL TEXT  

Distribution of Neisseria meningitidis Serogroup B Serosubtypes and Serotypes Circulating in the United States
Tondella et al.
J. Clin. Microbiol. 2000;38:3323-3328.
ABSTRACT | FULL TEXT  

There's Something About Serogroup B Meningococci
JWatch Infect. Diseases 1999;1999:19-19.
FULL TEXT